Keywords: emea, orphan, status, mgi, dacogen, pharma, biopharmaceutical

EMEA orphan status for MGI's Dacogen

Article | 07 August 2006

Print This

MGI Pharma, a US biopharmaceutical company focused in oncology and acute care, says that the European Medicines Agency (EMEA) has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in